Abcellera Biologics Inc ABCL

$11.93 +0.13 (1.10%)

Valuation

Market cap
3,618,010,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
3,136,800
Avg volume
7,039,568
Day's range
$11.75 – $12.28
Shares out
306,611,000
Stochastic %K
14%
Beta
1.41
Analysts
Strong Sell
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Stocktradesmoon Oct 19, 10:34 PM
$ABCL Get in NOW After Hours or Regret Missing OUT!! Read my Posts I have been right almost every time. Major catalyst Event in 3 days, this WEEK this Thursday, October 22, 2026 TMS Conference we get the 12 Week Data 📊 on the Impressive Phase II Results!!! We are going to MOON 🚀 to $18-$25!!! Just Watch and SEE!! 👀
1 replies
Amires Oct 19, 7:55 PM
$ABCL Called the reversal from $3–$4 when the short-covering was just brewing—check my posts since last November predicting the entire run to $12+. 🎯 ​The setup is shifting from a short-covering bounce to a full institutional re-rating: ​• P1 : 18M+ shorts covered, balance sheet locked down with $200M in cash. • P2: Pullback from $15 into the 12, cooled RSI right into major catalysts. ​Why the next leg is setting up: ​TMS Conference (Oct 22): Granular Phase 1/2 ABCL635 data drops in days. Top-line efficacy is already proven; clean safety and differentiation will drive the next wave. ​Wall St. Taking Notice: Analyst upgrades are already rolling in. Institutional accumulation is underway, and value investors need to move before the window closes. ​Q3 Earnings (Nov 9): Partner milestone updates (Vertex, Jazz) and pipeline clarity on ABCL688. ​This isn't just about trapped shorts anymore—it’s about $ABCL getting repriced as a validated clinical biotech. Eyes on the tape this week.
1 replies
Stocktradesmoon Oct 19, 7:51 PM
$ABCL 🚨 There are less than 3 days left to find out‼️. GET in NOW or MISS OUT on an ENORMOUS MOVE to $18-$25!!! It’s going to HAPPEN so FAST!!! 😮 🤯 🚀 💨 The BIG BEAST $ABCL is!! The ENTIRE WORLD is going to hear about it!! Can you imagine how many MILLIONS of People and INSTITUTIONS will be ADDING $ABCL to their Portfolios 💼 💉ABCL635 achieved with just ONE dose: 1) -83% in moderate/severe hot flashes vs Placebo: -33% 2) 5.3 fewer episodes PER DAY vs placebo 3) p&t;0.001 4) No serious adverse events in the first 4 weeks 💵And were talking about a market of approximately 12 MILLION women just in the US, of whom more than 6M are seeking treatment. 🗓️This Thursday 3 Days AWAY, October 22, they will present the Phase 2 12 WEEK Data 📊 at the World 🌎 2026 TMS Conference. 🔥And: JPMorgan initiates coverage of $ABCL with OVERWEIGHT and a price target of $18-$25 👀 Looks like well have a party for a few days. 🎉
2 replies
Stocktradesmoon Oct 19, 7:33 PM
$ABCL Agree! @XxZeeMoneyxX we get some positive news after hours today? Trap the bears on a solid run to 16 from Monday to Friday. Let’s gooooo!! -575 DATA 📊 (Carl said Oct 26’) -New Partnership -New Molecule -12 Week Data 📊 on Phase II Results All…Ahead of 2026 TMS Conference in 3 days October 22, 2026‼️ 🔥
1 replies
Stocktradesmoon Oct 19, 7:26 PM
$ABCL Last Chance to Buy here close to $12.00’sss!! Big Buy’s and Consolidation about done ✅ heading to $13.00’ss!!! This is GOING to be a HUGE Week for all of US!!! Shorts are all going to 🔥 burn!!
1 replies
Stocktradesmoon Oct 19, 7:24 PM
$ABCL
0 replies
Stocktradesmoon Oct 19, 7:15 PM
$ABCL
0 replies
Stocktradesmoon Oct 19, 7:13 PM
$ABCL AHEAD of the Major Catalyst in 3 days 🔥!!! 2026 TMS Conference, This Thursday, OCT 22, 26!!!
0 replies